These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37304310)

  • 1. Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.
    McLaughlin PJ; Sassani JW; Diaz D; Zagon IS
    J Diabetes Clin Res; 2023; 5(1):1-10. PubMed ID: 37304310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.
    Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ
    Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
    Diaz D; Sassani JP; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2024; 249():10175. PubMed ID: 38756167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the OGF-OGFr pathway in diabetic bone.
    Titunick MB; Lewis GS; Cain JD; Zagon IS; McLaughlin PJ
    Connect Tissue Res; 2019 Nov; 60(6):521-529. PubMed ID: 30931654
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of the OGF-OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2020 Sep; 245(15):1414-1421. PubMed ID: 32640891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of the OGF-OGFr pathway and associated diabetic complications.
    McLaughlin PJ; Sassani JW; Zagon IS
    J Diabetes Clin Res; 2021; 3(3):64-67. PubMed ID: 35252976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF.
    Purushothaman I; Zagon IS; Sassani JW; Zhou S; McLaughlin PJ
    Physiol Behav; 2021 Aug; 237():113436. PubMed ID: 33905807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.
    Purushothaman I; Zagon IS; Sassani JW; McLaughlin PJ
    Biochem Pharmacol; 2021 Oct; 192():114712. PubMed ID: 34324868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
    Sassani JW; Mc Laughlin PJ; Zagon IS
    J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea.
    Zagon IS; Ruth TB; Leure-duPree AE; Sassani JW; McLaughlin PJ
    Brain Res; 2003 Mar; 967(1-2):37-47. PubMed ID: 12650964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.